With the American Heart Association’s 2018 Scientific Sessions set for Nov. 10-12 in Chicago, two co-chairs of the programming committee previewed the themes of the meeting, its most anticipated clinical trials and the two new guidelines that will be unveiled.

Following President Trump’s recent comments about rescinding birthright citizenship in the U.S., one pediatric cardiologist is speaking out about his own history and career at Vanderbilt—a career, he says, that wouldn’t be possible without the 14th amendment.

A London, Kentucky, cardiologist was sentenced to 42 months in federal prison Oct. 31 after reportedly implanting “dozens” of unnecessary pacemakers and defrauding both his patients and their insurers, U.S. Attorney Robert M. Duncan, Jr., has announced.

ScieGen Pharmaceuticals has issued a recall of the blood pressure drug irbesartan after lab testing revealed a carcinogenic impurity, the FDA announced in a MedWatch Safety Alert.

A Stanford- and Apple-led atrial fibrillation study of more than 400,000 U.S. residents—the largest AFib screening effort to date—has entered its final phase of data collection, the company announced Nov. 1. The trial is expected to wrap up early next year.

DANVERS, Mass., Nov. 01, 2018 — Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2019 revenue of $181.8 million, an increase of 37% compared to revenue of $132.8 million for the same period of fiscal 2018.

Hospitals offering transcatheter aortic valve replacement (TAVR) tend to produce the best survival outcomes when both TAVR and surgical AVR (SAVR) caseloads remain high, according to a study published Oct. 31 in JAMA Cardiology.

Kidney dialysis is an independent predictor of mortality in end-stage renal disease (ESRD) patients undergoing transcatheter aortic valve implantation (TAVI), according to a seven-year trial of 2,000 men and women in Karlsruhe, Germany.

A study out of Binghamton University in New York suggests heart rate (HR) and blood pressure (BP) respond to environmental demands by undergoing allostasis rather than homeostasis, adding further evidence to a hypothesis scientists have mulled for years.

Another drug with the potential to lower cholesterol beyond maximally tolerated statin therapy is preparing to enter the marketplace, STAT reported on Oct. 28.